Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 4, 2009BloodOpen Access

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

View Full Paper
Ask AI
Bookmark
Share

Authors

CTConstantine S. TamThe Alfred HospitalTait D. ShanafeltTait D. ShanafeltRutgers, The State University of New JerseyWilliam G. WierdaWilliam G. WierdaBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tam et al. (2009) studied this question.

synapsesocial.com/papers/6a6f247d26770c2b8ddfdacfhttps://doi.org/10.1182/blood-2009-03-210591
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis2008 · 166 citations
  2. 2p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias1995 · 735 citations
  3. 3Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations
  4. 417p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.2005 · 58 citations
  5. 5Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia2007 · 562 citations